Palo Alto, California, March 20, 2025 (Globe Newswire) – KOS AI will be introducing the non-wearable, non-invasive blood glucose monitoring device, KOS Argus, at a press conference held at KOS AI headquarters in Palo Alto, California. The event provides insight into technology, its market potential, and the company’s regulatory pathway.
Innovate diabetes care
Argus offers needle-free alternatives to traditional glucose monitoring. Using multi-wavelength optical sensing and AI-driven analysis, the device continuously tracks glucose levels with a classification accuracy of 91.3% and sensitivity of 93.5%, and the sensitivity of hypoglycemia detection by 93.5%. Minimal calibration is required. This is an initial setup with optional refresh every 2-3 months.
“We are looking at a large global need for better glucose monitoring solutions,” explains Casey Nguyen, Head of Product Strategy at KOS AI. “Current monitoring methods are painful, expensive, or both, inadequate compliance and ultimately have poor health outcomes. Considering that the average person with diabetes who needs regular monitoring could perform 1,000 to 1,500 finger stab wounds, we can see why invasive alternatives aren’t converted.
Leadership and Development
KOS AI’s leadership team brings expertise across technology, compliance and product innovation. The CEO of Schalal Habib, five patents and 45 pending inventors, is leading the company’s vision.
Abhinav Agarwal, head of Machine Learning, a graduate of Stanford CS, developed the AI model for Argus and received the “Best Paper” at ICAIRME 2025 for research into the structured pruning of LLMS.
Ethics and Compliance Officer Chloe Truisillo manages regulatory compliance and clinical verification.
Casey Nguyen, Head of Product Strategy, drives product innovation and market positioning.
The continuous glucose monitoring market is projected to grow to $24.07 billion by 2030 from $13.13 billion in 2025. Adults affected by diabetes around the world may improve patient outcomes and promote recruitment. KOS AI is pursuing FDA clearance by the fourth quarter of 2025 and plans to expand into the consumer and healthcare markets.
Invitation to a press conference at KOS HQ
KOS AI invites members of the media, industry experts and investors to the exclusive announcement of the Argus System at KOS headquarters in Palo Alto. Participants will gain direct insight into technology and hear from the heart behind its development and witness this live demonstration of transformative health innovation.
Event details:
Date: March 20, 2025
Time: 3:00-4:00 pm pst
Location: KOS HQ, Stanford Research Park, 3000 El Camino Real, Building 3, Suite 120, Palo Alto, CA 94306
rsvp: media@kos-ai.com
Note: KOS Argus is currently undergoing clinical trials and is not available for commercial sales yet. Initial performance results are based on internal testing and individual results may vary.
About kos ai
KOS AI is a pioneering health technology company dedicated to developing AI-driven, non-invasive solutions for continuous health monitoring. KOS AI is redefineing the future of personal health management by integrating cutting-edge optical biosensing with advanced machine learning.
Media Contact:
Communication Team KOS AI
media@kos-ai.com
lol. kos-ai.com
424-274-7131
Disclaimer: The expert opinions presented in this PR/story are based on the extensive experience and knowledge of the source company. These views do not necessarily reflect the opinions of news distribution companies and their distribution partners. There are no offers to sell, no solicitation of offers to buy, nor are there any medical, product or service recommendations in this article. Furthermore, what is included in this should not be construed as medical advice or recommendations for starting, stopping or modifying treatment or medication. It is your responsibility to determine whether your medical, product or service is suitable for you based on your health purpose, medical condition, and risk tolerance. Consult your healthcare provider about your specific medical situation.
Press conference on KOS AI To HOST ARGUS: Non-invasive Blood Glucose Monitoring Breakthrough
